logo

Axovant Sciences Ltd. (AXON)



Trade AXON now with
  Date
  Headline
10/25/2018 2:47:22 AM Axovant Sciences Doses First Patient In Clinical Study Of AXO-Lenti-PD
7/8/2018 8:45:41 PM Axovant Announces Licensing Agreement For AXO-AAV-OPMD Program For Treatment Of Oculopharyngeal Muscular Dystrophy
6/6/2018 2:15:05 AM Oxford BioMedica Enters Exclusive Worldwide Licensing Agreement With Axovant
6/6/2018 2:05:50 AM Axovant Sciences Licenses Exclusive Worldwide Rights To Develop OXB-102, Now AXO-Lenti-PD, From Oxford BioMedica
2/12/2018 7:02:11 AM Axovant Sciences CEO David Hung Resigns To Pursue Other Opportunities
1/8/2018 7:09:24 AM Axovant: Intepirdine Did Not Meet Primary Efficacy Endpoints In Phase 2b HEADWAY, Pilot Phase 2 Gait And Balance Studies
2/10/2016 8:52:09 AM RBC Capital Markets Is Cutting Axovant Sciences Ltd. (AXON) 2018 Estimate To -2.85 From -1.99
2/10/2016 8:51:52 AM RBC Capital Markets Is Cutting Axovant Sciences Ltd. (AXON) 2017 Estimate To -2.51 From -1.41